Autolus Therapeutics (AUTL) Non-Current Assets (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Non-Current Assets data on file, last reported at $153.2 million in Q4 2025.

• Quarterly Non-Current Assets rose 25.75% year-over-year to $153.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $577.8 million (up 36.49% YoY) and the FY2025 annual result came in at $153.2 million, up 25.75% from the prior year.
• Non-Current Assets advanced to $153.2 million in Q4 2025, from $147.4 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $153.2 million in Q4 2025 to a low of $2.5 million in Q3 2021.
• A 5-year average of $82.7 million and a median of $95.3 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2021 — Non-Current Assets dropped 13.08% — and 2022, when it jumped 1950.92%.
• Tracing AUTL's Non-Current Assets over 5 years: stood at $58.6 million in 2021, then gained by 10.06% to $64.5 million in 2022, then soared by 55.15% to $100.1 million in 2023, then gained by 21.7% to $121.8 million in 2024, then climbed by 25.75% to $153.2 million in 2025.
• The last three Non-Current Assets figures came in at $153.2 million (Q4 2025), $147.4 million (Q3 2025), and $146.7 million (Q2 2025), per Business Quant data.